Follitropin beta

Indications & Dose:

Ovulation induction: Induction of ovulation and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure. Follicle stimulation: Stimulation of the development of multiple follicles in ovulatory patients undergoing assisted reproductive technologies such as in vitro fertilization. Spermatogenesis induction: Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypopgonadism is whom the cause of infertility is not due to primary testicular failure.

DOSAGE: Follitropin Alpha : Adults: SC: Ovulation induction: Initial recommended dose of the first cycle: 75 international units/day. Consider dose adjustment after 5-7 days; additional dose adjustments of up to 37.5 international units may be considered after 14 days. Further dose increases of the same magnitude can be made, if necessary, every 7 days. To complete follicular development and effect ovulation in the absence of an endogenous LH surge, give 5000 to 10,000 units hCG, 1 day after the last dose of follitropin alpha. Withhold hCG if serum estradiol is >2000 pg/mL. Follitropin
Beta: There are great inter-and intra-individual variations in the response of the ovaries to exogenous gonadotropins. This makes it impossible to set a uniform dosage scheme. In general, a sequential treatment scheme is recommended. This usually starts with daily administration of 75IU FSH activity. The starting dose is maintained for at least seven days. If there is no ovarian response, the daily dose is then gradually increased until follicle growth and/or plasma estradiol levels indicate an adequate pharmacodynamic response. A daily increase in estradiol to be optimal. The daily dose is then maintained until preovulatory conditions are reached. Usually, 7 to 14 days of treatment are sufficient to reach this state. 

Contraindications:

Tumors of ovary, breast, uterus, piturity or hypothalamus. Pregnancy or lactation Undiagnosed vaginal bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (PCOD) 

Side Effects:

Unwanted ovarian hyperstimulation has been observed. Clinical use by the IM or SC  routes may lead to reactions at the site of injection, such as bruising, pain redness, swelling and itching, the majority of which are mild. Generalized reactions have not been observed. A slightly increased risk of ectopic pregnancy and multiple gestations has been seen.
PREGNANCY: Pregnancy risk factor is X. 

Cautions:

Precautions:

The presence of uncontrolled nongonadal endocrinopathies. Should be excluded. In pregnancies occurring after induction of ovulation
with gonadotropic preparations. There is an increased risk of multiple gestations. Since infertile women undergoing assisted reproduction, and particularly IMF, often have tubal abnormalities, the incidence of ectopic pregnancies might be increased. Rates of pregnancy loss in women undergoing ART  are higher than in the normal population. 

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: